title: Debugging the Black Box.
abstract: <b/> A better understanding of the mechanisms by which tumor rejection succeeds and fails is needed to improve immunotherapies. Here, Anagnostou and colleagues find that mutations predicted to be the most immunogenic are preferentially lost when cancer progresses through checkpoint blockade.Cancer Discov; 7(3); 250-1. ©2017 AACRSee related article by Anagnostou et al., p. 264.
authors.affiliation: Surgery Branch, National Cancer Institute, Bethesda, Maryland. JamesYang@mail.nih.gov.
authors.forename: James C
authors.initials: JC
authors.lastname: Yang
mesh_terms: D006801:Humans; D007167:Immunotherapy; D009154:Mutation; D009369:Neoplasms / Q000235:genetics*